<DOC>
	<DOCNO>NCT01553786</DOCNO>
	<brief_summary>This study aim evaluate efficacy lenalidomide associate CHOP measure complete response rate end treatment . Approximately 80 patient age 60 80 year include , 70 evaluable patient . The treatment consist two phase four 3-weeks cycle : induction phase consolidation phase , total treatment duration 24 week . Each cycle break follow : chemotherapy administer hospital day 1 , prednisone continue 5 day lenalidomide take 14 day . Patients follow least 18 month inclusion last patient .</brief_summary>
	<brief_title>Efficacy Treatment With CHOP Lenalidomide First Line Angioimmunoblastic T-cell Lymphoma ( AITL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients histologically proven Tcell angioimmunoblastic lymphoma ( AITL ) Age 60 80 year . Eastern Cooperative Oncology Group performance status 0 2 . No previous therapy ( except corticosteroid provide initiate less 15 day inclusion ) . Spontaneous life expectancy &gt; 1 month . Written informed consent . The Lenalidomide Information Sheet ( appendix N protocol ) give patient receive lenalidomide study therapy . The patient must read document prior start lenalidomide study treatment time receive new supply study drug . Male patient must : Agree use condom sexual contact FCBP , even vasectomy , throughout study drug therapy , dose interruption cessation study therapy . Agree give semen sperm study drug therapy period end study drug therapy . All patient must : Have understand study drug could potential teratogenicity . Agree abstain donate blood take study drug therapy follow discontinuation study drug therapy . Agree share study medication another person . Be counselled pregnancy precaution risk foetal exposure . Others category Tcell lymphoma . Central nervous system involvement lymphoma . Any previous therapy lymphoma except shortterm corticosteroid ( maximum 10 day ) inclusion . Contraindication drug include CHOP regimen . Serious medical psychiatric illness likely interfere participation clinical study ( accord investigator 's decision ) . Active bacterial , viral fungal infection , particular active hepatitis B C HIV positive serological test . Impaired renal function ( Creatinine clearance &lt; 50 ml/min ( calculate CockcroftGault formula ) ) impair liver function test ( total bilirubin level &gt; 30 Âµmol/L , transaminases &gt; 2.5 upper normal limit ) unless relate lymphoma . Poor bone marrow reserve define neutrophil &lt; 1.0 x 109/L platelet &lt; 100 x 109/L , unless relate bone marrow infiltration . Any history malignancy , treat research , unless patient remain free disease 5 year . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Hypersensitivity active substance excipients . Pregnant lactate woman Females Childbearing potential ( FCBP* ) accord Pregnancy Prevention Plan appendix L protocol ) The Pregnancy Prevention Plan define female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy 2 ) naturally postmenopausal ( amenorrhea follow cancer therapy rule childbearing potential ) least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>T-cell lymphoma</keyword>
	<keyword>CHOp</keyword>
	<keyword>lenalidomide</keyword>
</DOC>